Olmesartan Medoxomil AND Hydrochlorothiazide

APR 23, 2026 · REGULATORY LABEL UPDATE

FDA supplemental approval: Olmesartan Medoxomil AND Hydrochlorothiazide (Labeling)

U.S. Food and Drug Administration

FDA supplemental approval of a labeling change for an existing combination antihypertensive; does not contain clinical trial data or efficacy evidence.